Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
JACC. Heart failure • Vol. 8, Issue 4 • 2020
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lancet (London, England) • Vol. 378, Issue 9792 • 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Lancet (London, England) • Vol. 378, Issue 9792 • 2011
Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
ACS medicinal chemistry letters • Vol. 1, Issue 9 • 2010
